James Jarrett

James Jarrett

Auto-generated profile, based on publicly available information

James Jarrett

Gilead Sciences Inc., Foster City, CA 94404, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2025 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
PSPatrick S. Sullivan
Patrick S. Sullivan
CCCillian Copeland
Cillian Copeland
JJJames Jarrett
James Jarrett
UMUche Mordi
Uche Mordi
NKNikos Kotsopoulos
Nikos Kotsopoulos
HTHansel E. Tookes
Hansel E. Tookes
Introduction International guidelines emphasize the need for earlier commencement of antiretroviral therapy (ART) among people with HIV (PWH). Reducing the time between HIV diagnosis and ART initiation can improve health outcomes, reduce healthcare utilization, and reduce HIV transmissions. This study evaluated the clinical and economic benefits associated with increasing uptake of rapid start ART among newly diagnosed PWH. Methods A state transition disease model was developed in the United States setting to evaluate the benefits from earlier initiation of ART. The base case analysis compared two cohorts of 1000 newly diagnosed PWH: one following current patterns of ART initiation, and a counterfactual cohort where those receiving rapid start ART was doubled. Individuals were classified by different CD4 states at diagnosis and over time with viral suppression rates also being tracked. ART and CD4 state-specific healthcare costs were estimated over a 3-year time horizon. Averted HIV transmissions were calculated and used to estimate lifetime healthcare cost savings while CD4-specific mortality was also calculated. Several scenario analyses explored alternate assumptions related to the time at which PWH started ART after diagnosis. Results Doubling the proportion of newly diagnosed PWH receiving rapid start ART averted 7 HIV transmissions and 0.3 deaths per 1000 people, corresponding to numbers needed to treat of 141 and 3502, respectively. This leads to cost savings resulting from reduced healthcare resource use and lifetime cost savings from preventing new HIV transmissions. Conclusion Reducing the time between HIV diagnosis and ART initiation can provide clinical and economic benefits by eliminating transmissions that might occur while individuals are viremic but not on treatment. The additional costs of providing ART required for this increase achieve high levels of return when considering the lifetime healthcare cost burden of onward HIV transmissions potentially averted by early ART start.

1 October 2025 in ClinicoEconomics and Outcomes Research
Verified
Journal Article
Open access
PDF file
CCCillian Copeland
Cillian Copeland
RMRui Martins
Rui Martins
RTRyan Thaliffdeen
Ryan Thaliffdeen
NKNikos Kotsopoulos
Nikos Kotsopoulos
JJJames Jarrett
James Jarrett
MPMaarten J. Postma
Maarten J. Postma
Background: The United States (US) HIV/AIDS strategy has targeted a 90% reduction in HIV infections by 2030. Whilst progress has been made in US HIV policy, the persistence of nearly 32,000 new infections annually highlights substantial barriers that still hinder effective treatment and the achievement of national targets. While the humanistic burden of HIV is well documented, there are broader economic effects on employment, disability and retirement. The objective of this study is to evaluate these economic gains when improving various HIV policies. Methodology: This analysis adapts a published Markov model assessing the role of six key policy parameters related to diagnosis, pre-exposure prophylaxis (PrEP) uptake, treatment initiation, and treatment as prevention (TasP) on the HIV epidemic in the US. Improvements in these parameters were explored to estimate averted HIV infections over 50 years and, subsequently, the feasibility of achieving the 2030 target of a 90% reduction in HIV incidence. A fiscal economic framework was also applied, linking HIV cases and policy targets to productivity, tax revenue, transfer benefits, and healthcare costs incurred by the US government. Results: Results were calculated for the general US population and for men who have sex with men (MSM), a subgroup experiencing a high HIV burden. For the general US population, policy improvements led to an average of 5,324 averted HIV infections annually over the 50-year horizon, corresponding to a total net annual fiscal gain of $397 million or $74,511 per averted infection. For the MSM subgroup, 911 infections were averted annually resulting in a net fiscal gain of $96 million, or $105,031 per averted infection. Conclusion: This analysis demonstrates that the benefits of HIV policy are not limited to the healthcare setting and show how initial investments provide long-term benefits by preventing HIV transmission and the associated impact on individuals’ labor market outcomes. While relying on assumptions and projections that may not capture all real-word complexities, fiscal analyses can provide a useful tool for policy evaluation that facilitate a holistic assessment of the wider costs and benefits that fall on governments as well as benefits of achieving policy targets.

26 March 2026 in Journal of Health Economics and Outcomes Research
Verified
Journal Article
Open access
PDF file
HTHansel E. Tookes
Hansel E. Tookes
CCCillian Copeland
Cillian Copeland
UMUche Mordi
Uche Mordi
JJJames Jarrett
James Jarrett
RMRui Martins
Rui Martins
PSPatrick S. Sullivan
Patrick S. Sullivan
Background: Antiretroviral therapy (ART) has become a cornerstone of human immunodeficiency virus (HIV) management. However, a challenge in HIV care and policy is ensuring individuals remain engaged in care and on treatment over time. Discontinuation of ART is common for various reasons, and prolonged treatment interruptions can lead to worse health outcomes at the individual level and increased HIV transmissions at the public health level. Objective: A cost-consequence analysis was conducted to evaluate the economic and public health impact of reducing the interval to ART restart among people with HIV (PWH) who have disengaged from care. Methods: A state transition disease model was developed to calculate the economic benefits from improving treatment restart patterns from a United States healthcare payer perspective. Two hypothetical cohorts of 1000 PWH who discontinued ART were compared: a standard-of-care cohort where restart occurs 32 weeks after discontinuation, and a comparator cohort exploring the impact of reducing the time between ART discontinuation and restart to 12 weeks. Individuals were assigned to CD4-related health states, and rates of viral suppression were considered. Four outcomes, ART costs, CD4 health state costs, CD4-related mortality, and new HIV transmissions were calculated over a three-year time horizon. Cost savings from averted HIV cases were valued based on the lifetime excess healthcare costs for a PWH. Results: Increasing the proportion of individuals restarting ART and reducing time to restart was estimated to avert 88 HIV transmissions. This corresponds to a number needed to treat, defined as the number of PWH who would need to experience the earlier restart pattern of the comparator cohort, of 11 to avoid one new transmission, and $101 083 857 lifetime cost savings. Cost savings attributable to improved CD4 counts in the cohort were also found. Conclusion: Enhancing ART restart patterns improves health and provides considerable cost savings by improving individuals’ CD4 counts and reducing new HIV transmissions from people who are viremic. Effective policies to promote care engagement and treatment adherence are predicted to improve the health of PWH and reduce new HIV cases.

1 November 2026 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
TCTristan Curteis
Tristan Curteis
AFAidan N Franklin
Aidan N Franklin
RJRebecca K Judge
Rebecca K Judge
AZAnna Zolotor
Anna Zolotor
JJJames Jarrett
James Jarrett
DMDylan Mezzio
Dylan Mezzio
Background: Given the effectiveness of pre-exposure prophylaxis (PrEP), the HIV prevention landscape is expanding rapidly – including recently approved injectable options which have shown high efficacy in clinical trials. As head-to-head trials of injectable PrEPs are not feasible, indirect treatment comparisons (ITCs) are of value to generate comparative estimates of efficacy and safety. However, several methodological challenges must be carefully considered when conducting these ITCs. This review outlines these complexities to support informed decision-making. Main text: We identified methodological considerations through a narrative review of available literature (including leveraging published systematic reviews), evidence from PrEP trials and, where applicable, reference to methodological guidelines. Our review suggests treatment effect modifiers (TEMs) for PrEP are poorly defined in the HIV PrEP literature and, due to the high efficacy of injectable compared with oral PrEP, encompass potential prognostic factors (such as background HIV incidence). Challenges in comparing potential TEMs across trials were also noted due to, for example, differences in measurement methodology and reporting timepoint for adherence. Accounting for variation in follow-up across studies within potential ITCs is critical as HIV acquisition is a rare, time-dependent event. Additionally, zero or few events occur within injectable PrEP trials in HIV, challenging variance estimation and necessitating alternative statistical approaches. Population-adjustment methods are similarly complicated. Conclusions: This review outlines key considerations and offers practical recommendations to inform robust conduct of ITCs of PrEP, and support the interpretation of results. Areas of further research to strengthen future comparative evidence are also highlighted.

6 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JDJoseph S. Doyle
Joseph S. Doyle
PKPhillip Keen
Phillip Keen
VDValerie Delpech
Valerie Delpech
LELouise Evans
Louise Evans
LBLaurel Bates
Laurel Bates
MRMurad Ruf
Murad Ruf
Background: Despite significant progress towards global elimination targets of blood-borne viruses (BBVs) in Australia, many individuals remain undiagnosed or receive a late diagnosis, particularly those underserved by current testing strategies. An estimated 31% of hepatitis B (HBV), 16% of hepatitis C (HCV), and 8% of human immunodeficiency virus (HIV) infections remain undiagnosed. This study evaluates the potential health and economic benefits of emergency department (ED) opt-out testing (OOT) for BBVs in Australia's highest-prevalence areas.Methods: We developed a hybrid cost-effectiveness model to compare projected outcomes of ED BBV OOT with current testing in ED as standard of care (SoC). A decision tree simulated testing and linkage to care (LTC) for ED attendees requiring blood tests who do not opt out; a Markov model estimated long-term outcomes. Primary outcomes were the number of new diagnoses, number LTC, quality-adjusted life years (QALYs) and healthcare costs, using a national health service perspective over a lifetime.Findings: ED OOT resulted in 32 incremental new BBV diagnoses per 10,000 attendees compared to SoC. Additionally, an incremental 17 and 37 BBV patients per 10,000 were newly or re-linked to care, respectively. Combined testing for all three BBVs was highly cost-effective, with an incremental cost per QALY gained of $3,273 over a patient’s lifetime.Interpretation: Scaling up real-world ED BBV OOT could transform early diagnosis and move Australia closer to ending preventable BBV infections and meeting transmission elimination goals.